Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ipragliflozin-L-Proline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Suglat

    02 1Sujanu

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Suglat

    Ipragliflozin

    arrow
    AOCS Annual Meeting
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    AOCS Annual Meeting
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 248

    2019 Revenue in Millions : 209

    Growth (%) : 19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Suglat

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 253

    2020 Revenue in Millions : 247

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Suglat

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 231

    2021 Revenue in Millions : 256

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Sujanu

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Sujanu

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 94

    2021 Revenue in Millions : 106

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Suglat

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2018 Revenue in Millions : 139

    2017 Revenue in Millions : 106

    Growth (%) : 31%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Suglat

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2016 Revenue in Millions : 82

    2015 Revenue in Millions : 57

    Growth (%) : 44

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Suglat

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2019 Revenue in Millions : 212

    2018 Revenue in Millions : 143

    Growth (%) : 48

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Suglat

    Ipragliflozin

    arrow
    Arvo
    Not Confirmed

    Brand Name : Suglat

    Japan
    arrow
    Arvo
    Not Confirmed

    Astellas Pharma

    Ipragliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2017 Revenue in Millions : 113

    2016 Revenue in Millions : 87

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.